Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.32 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31674277 | 0.88 | FFAR4 (0.36) | FFAR4FFAR1PDPK1CHRNA7MEP1A | |
| SCHEMBL23782788 | 0.84 | FFAR1 (0.46) | FFAR4FFAR1PDPK1 | |
| SCHEMBL4715993 | 0.84 | CES2 (0.41) | FFAR4FFAR1CHRNA7 | |
| SCHEMBL29010022 | 0.79 | HDAC3 (0.43) | FFAR4FFAR1 | |
| SCHEMBL30428485 | 0.79 | HDAC3 (0.43) | FFAR4FFAR1 | |
| SCHEMBL30427812 | 0.77 | F13A1 (0.46) | FFAR4FFAR1 | |
| SCHEMBL17605475 | 0.76 | IAPP (0.34) | FFAR4FFAR1PDPK1MEP1B | |
| SCHEMBL29604497 | 0.76 | PDPK1 (0.43) | FFAR4FFAR1PDPK1 | |
| SCHEMBL3515626 | 0.76 | PDPK1 (0.56) | FFAR4FFAR1PDPK1CHRNA7 | |
| SCHEMBL28743936 | 0.76 | PDPK1 (0.43) | FFAR4FFAR1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | FFAR4 4696/4885FFAR1 4554/4885PDPK1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.